Zhongda'an: Wu Junye, the controlling shareholder, plans to reduce his holdings by no more than 2%

Big Pharma CCHT’s Domination Unlikely to Fade Soon Despite Official Bulk Buying

The producer of long-acting growth hormone acupunctures, vaccines and other drugs, looks set to offset the effects of so-called “centralized procurement” on its product prices with more aggressive expansion into private hospitals. So far, its monopoly appears unshakable, but with more competitors upping the stakes, how long will it last?

Thinking of ASEAN as a single market is the biggest miscalculation for Chinese companies

For a long time, multinational corporations have often held a dangerous "holistic" bias when examining the Association of Southeast Asian Nations (ASEAN). This perspective views ASEAN—a region with over 690 million people and interwoven diverse cultures—as a single emerging market, attempting to capture one country as a model and then replicating that pattern across other member states.

China Embodied AI Data Platform Maniformer Raises Hundreds of Mns RMB,Led by Sequoia China

Recently, China embodied AI data platform Maniformer (觅蜂科技) announced the completion of several hundred million RMB in seed and angel financing.

Unpacking China | Key Chinese Firms to Watch This Week （08/02/2026-14/02/2025）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Linkerbot Secures Nearly CNY 1.5 Billion in Series B Funding

February 12 News – Linkerbot (灵心巧手), a leader in the dexterous hand sector, has completed a Series B financing round of nearly CNY 1.5 billion.